Scientific Programme & Abstracts from the International Meeting in Pediatric Endocrinology (IMPE)

impe0096fc16.1 | Thyroid 2 | IMPE2023

A Retrospective Analysis of Patients with Pediatric Papillary Thyroid Cancer not Treated with RAI: Is Less More?

E Castellanos Luz , E Zafereo Mark , R Wang Jennifer , K Ying Anita , G Waguespack Steven

Background: Pediatric papillary thyroid cancer (PTC) is traditionally treated with total thyroidectomy and radioactive iodine (RAI). However, growing evidence suggests that not all patients benefit from RAI. Our objective was to describe clinicopathologic features and outcomes of patients with pediatric PTC who did not receive upfront adjuvant RAI therapy.Methods: Using an IRB-approved database at a tertiary referral can...

impe0096fc5.1 | Fat, Metabolism and Obesity | IMPE2023

Evaluation of Clinical Benefit Following Setmelanotide Treatment in Patients With Bardet-Biedl Syndrome

Haqq Andrea M. , K. Chung Wendy , Dollfus Hélène , Iqbal Anoop , Á. Martos-Moreno Gabriel , Poitou Christine , A. Yanovski Jack , Malhotra Sonali , Miller Paul , Yuan Guojun , Forsythe Elizabeth , Clément Karine , Argente Jesús

Bardet-Biedl syndrome (BBS) is a rare disease associated with signaling defects in the melanocortin-4 receptor (MC4R) pathway that lead to hyperphagia, severe obesity, and, consequently, reduced quality of life (QOL). We investigated the impact of setmelanotide, an MC4R agonist, on weight, body composition, hunger, and QOL in a Phase 3 trial of patients with BBS to characterize clinically meaningful and patient-relevant benefit. Patients aged ≥6 years with BBS and obesity w...